Evaluation of the safety of fenbendazole in cats

Schwartz, Roger D.; Donoghue, Ann R.; Baggs, Raymond B.; Clark, Theodore G.; Partington, Carol

doi:10.2460/ajvr.2000.61.330

Cited by 23 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When given therapeutically to nonpregnant animals, benzimidazoles produce few adverse effects, even when given in doses several times in excess of those recommended. Thus, fenbendazole produced no adverse effects in cats when given at up to five times the recommended dose and three times the recommended duration (Schwartz et al, 2000). No toxic effects were seen in cattle given 2000 mg/kg body weight fenbendazole (the therapeutic dose is around 5 mg/kg body weight) (Muser & Paul, 1984).…”

Section: Benzimidazole Anthelmintic Drugsmentioning

confidence: 99%

Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies

Woodward¹

2005

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Toxicological studies are conducted on constituents of veterinary medicinal products for a number of reasons. Aside from being a requirement of legislation, they are carried out for predictive purposes in the assessment of user safety or for the determination of consumer safety, for example, in the elaboration of maximum residue limits or tolerances. Alternatively, the results of toxicology studies may be available as they have been generated for registration of the drug for human medicinal purposes. This paper examines if the results of such studies have any predictive value for adverse reactions, which might occur during clinical use in animals. A number of adverse reactions, notably the Type A (toxicology or pharmacology dependent) should be predictable from these laboratory studies. However, as with human pharmaceutical products, they have less utility in predicting Type-B reactions (idiosyncratic in nature).

show abstract

Section: Benzimidazole Anthelmintic Drugsmentioning

confidence: 99%

Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies

Woodward¹

2005

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…11,12 FEN has demonstrated very low toxicity in various animal species including dogs. [13][14][15][16] Moreover, several studies conducted on cancer cell treatment reported positive effects of FEN. Chu et al demonstrated that benzimidazoles such as FEN and albendazole destroyed microtubules, induced apoptosis, and inhibited drug resistance in human ovarian cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles

Shin

Jin

et al. 2021

IJN

View full text Add to dashboard Cite

We aimed to develop a nanocarrier formulation incorporating fenbendazole (FEN) and rapamycin (RAPA) with strong efficacy against A549 cancer cells. As FEN and RAPA are poorly soluble in water, it is difficult to apply them clinically in vivo. Therefore, we attempted to resolve this problem by encapsulating these drugs in polymeric micelles. Methods: We evaluated drug synergy using the combination index (CI) values of various molar ratios of FEN and RAPA. We formed and tested micelles composed of different polymers. Moreover, we conducted cytotoxicity, stability, release, pharmacokinetic, and biodistribution studies to investigate the antitumor effects of FEN/RAPA-loaded mPEG-b-PCL micelles. Results: We selected mPEG-b-PCL-containing FEN and RAPA at a molar ratio of 1:2 because these particles were consistent in size and had high encapsulation efficiency (EE, %) and drug loading (DL, %) capacity. The in vitro cytotoxicity was assessed for various FEN, RAPA, and combined FEN/RAPA formulations. After long-term exposures, both the solutions and the micelles had similar efficacy against A549 cancer cells. The in vivo pharmacokinetic study revealed that FEN/RAPA-loaded mPEG-b-PCL micelles had a relatively higher area under the plasma concentration-time curve from 0 to 2 h (AUC 0-2 h ) and 0 to 8 h (AUC 0-8 h ) and plasma concentration at time zero (C o ) than that of the FEN/RAPA solution. The in vivo biodistribution assay revealed that the IV injection of FEN/RAPA-loaded mPEGb-PCL micelles resulted in lower pulmonary FEN concentration than the IV injection of the FEN/RAPA solution. Conclusion: When FEN and RAPA had a 1:2 molar ratio, they showed synergism. Additionally, using data from in vitro cytotoxicity, synergism between a 1:2 molar ratio of FEN and RAPA was observed in the micelle formulation. The FEN/RAPA-loaded mPEGb-PCL micelle had enhanced bioavailability than the FEN/RAPA solution.

show abstract

“…Fenbendazole (methyl N-(6-phenylsulfanyl-1Hbenzimidazol-2-yl) carbamate) is a broadspectrum benzimidazole anthelmintic that contains anti-proliferative activity and is typically used in veterinary medicine to target parasitic pinworms. Fenbendazole is also known to have low degree of toxicity and high degree of safety in animals [26][27][28][29][30]. Fenbendazole is used to target gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia -excluding dipylidium caninum, which is a common dog tapeworm -, pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides.…”

Section: Fenbendazolementioning

confidence: 99%

Potential Hexokinase II Inhibition by Benzimidazole Anthelmintics: Albendazole, Mebendazole and Fenbendazole

Kim

2021

JPRI

View full text Add to dashboard Cite

The nitrogen heterocycle benzimidazoles have been known to be anthelmintic drugs. Beyond that role, the benzimidazoles exhibit other pharmacological potential as anti-inflammatory, antiulcer, anti-hypertensive and anticancer agents. A growing body of evidence supports the anticancer efficiency via treatment with benzimidazoles. The target proteins for pharmacological effect appear to be cell microtubules. However, it has been reported that the benzimidazoles could inhibit hexokinase II, which is a critical factor in the glycolysis pathway in humans. Here, we discuss on the most common benzimidazoles such as albendazole, mebendazole and fenbendazole and focus on the potential anticancer activities of the target enzyme hexokinase II. This review would give better insight in development of target-specific benzimidazole derivatives as potential anticancer therapeutics.

show abstract

Evaluation of the safety of fenbendazole in cats

Abstract: Fenbendazole administered to healthy cats at a dosage 5 times the dosage and 3 times the duration approved for use in dogs and wild felids did not cause any acute or subacute adverse reactions or pathologic changes. Results suggest that cats may be safely treated with fenbendazole.

Cited by 23 publications

References 6 publications

Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies

Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies

Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles

Potential Hexokinase II Inhibition by Benzimidazole Anthelmintics: Albendazole, Mebendazole and Fenbendazole

Contact Info

Product

Resources

About